Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains

Brain, Behavior, and Immunity

Volumn 25, Issue 6, 2011, Pages 1223-1232

  Liu, Liang ^a   Coller, Janet K ^a   Watkins, Linda R ^b   Somogyi, Andrew A ^a   Hutchinson, Mark R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Glia; Interleukin 1 ; Mice strain differences; Morphine; MyD88; Tolerance; Toll like receptor 4; Withdrawal

Indexed keywords

INTERLEUKIN 1BETA; MORPHINE; MYELOID DIFFERENTIATION FACTOR 88; NALOXONE; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; BRAIN STEM; CONTROLLED STUDY; DIENCEPHALON; DRUG DEPENDENCE; GENE SEQUENCE; HIPPOCAMPUS; MALE; MESENCEPHALON; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRECIPITATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; CELLS, CULTURED; DRUG TOLERANCE; HIPPOCAMPUS; INFLAMMATION; INTERLEUKIN-1BETA; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; MORPHINE DEPENDENCE; MOTOR ACTIVITY; MYELOID DIFFERENTIATION FACTOR 88; NALOXONE; NARCOTIC ANTAGONISTS; NEUROGLIA; NEUROIMMUNOMODULATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; SUBSTANCE WITHDRAWAL SYNDROME; TOLL-LIKE RECEPTOR 4;

EID: 79960272632     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.03.016     Document Type: Article

References (38)

1. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9:143-150.
2. Belknap J.K., Riggan J., Cross S., Young E.R., Gallaher E.J., Crabbe J.C. Genetic determinants of morphine activity and thermal responses in 15 inbred mouse strains. Pharmacol. Biochem. Behav. 1998, 59:353-360.
3. Bell E. TLR signalling. Nat. Rev. Immunol. 2003, 3:692.
4. Bland S.T., Hutchinson M.R., Maier S.F., Watkins L.R., Johnson K.W. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav. Immun. 2009, 23:492-497.
5. Bohn L.M., Gainetdinov R.R., Lin F.T., Lefkowitz R.J., Caron M.G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408:720-723.
6. Bryant C.D., Roberts K.W., Byun J.S., Fanselow M.S., Evans C.J. Morphine analgesic tolerance in 129P3/J and 129S6/SvEv mice. Pharmacol. Biochem. Behav. 2006, 85:769-779.
7. Frenois F., Cador M., Caille S., Stinus L., Le Moine C. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur. J. Neurosci. 2002, 16:1377-1389.
8. Giraldo J., Vivas N.M., Vila E., Badia A. Assessing the (a)symmetry of concentration-effect curves: empirical versus mechanistic models. Pharmacol. Ther. 2002, 95:21-45.
9. Gol'dberg E., Masnaya N., Churin A. Immunity parameters in mice of different strains. Bull. Exp. Biol. Med. 2005, 140:219-221.
10. Hutchinson M.R., Bland S.T., Johnson K.W., Rice K.C., Maier S.F., Watkins L.R. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci. World J. 2007, 7:98-111.
11. Hutchinson M.R., Coats B.D., Lewis S.S., Zhang Y., Sprunger D.B., Rezvani N., Baker E.M., Jekich B.M., Wieseler J.L., Somogyi A.A., Martin D., Poole S., Judd C.M., Maier S.F., Watkins L.R. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav. Immun. 2008, 22:1178-1189.
12. Hutchinson M.R., Northcutt A.L., Chao L.W., Kearney J.J., Zhang Y., Berkelhammer D.L., Loram L.C., Rozeske R.R., Bland S.T., Maier S.F., Gleeson T.T., Watkins L.R. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav. Immun. 2008, 22:1248-1256.
13. Hutchinson M.R., Lewis S.S., Coats B.D., Skyba D.A., Crysdale N.Y., Berkelhammer D.L., Brzeski A., Northcutt A., Vietz C.M., Judd C.M., Maier S.F., Watkins L.R., Johnson K.W. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain. Behav. Immun. 2009, 23:240-250.
14. Hutchinson M.R., Zhang Y., Shridhar M., Evans J.H., Buchanan M.M., Zhao T.X., Slivka P.F., Coats B.D., Rezvani N., Wieseler J., Hughes T.S., Landgraf K.E., Chan S., Fong S., Phipps S., Falke J.J., Leinwand L.A., Maier S.F., Yin H., Rice K.C., Watkins L.R. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav. Immun. 2010, 24:83-95.
15. Johnston I.N., Milligan E.D., Wieseler-Frank J., Frank M.G., Zapata V., Campisi J., Langer S., Martin D., Green P., Fleshner M., Leinwand L., Maier S.F., Watkins L.R. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J. Neurosci. 2004, 24:7353-7365.
16. Kest B., Hopkins E., Palmese C.A., Adler M., Mogil J.S. Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. Pharmacol. Biochem. Behav. 2002, 73:821-828.
17. Kest B., Palmese C.A., Hopkins E., Adler M., Juni A., Mogil J.S. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 2002, 115:463-469.
18. Kosten T.R., George T.P. The neurobiology of opioid dependence: implications for treatment. Sci. Pract. Perspect. 2002, 1:13-20.
19. Li Y., Li H., Zhang Y., Sun X., Hanley G.A., LeSage G., Zhang Y., Sun S., Peng Y., Yin D. Toll-like receptor 2 is required for opioids-induced neuronal apoptosis. Biochem. Biophys. Res. Commun. 2010, 391:426-430.
20. Liang D.Y., Guo T., Liao G., Kingery W.S., Peltz G., Clark J.D. Chronic pain and genetic background interact and influence opioid analgesia, tolerance, and physical dependence. Pain 2006, 121:232-240.
21. Liang D.Y., Liao G., Wang J., Usuka J., Guo Y., Peltz G., Clark J.D. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 2006, 104:1054-1062.
22. Liu L., Hutchinson M.R., White J.M., Somogyi A.A., Coller J.K. Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenet. Genomics 2009, 19:869-876.
23. Masnaya N.V., Churin A.A., Borsuk O.S., Sherstoboev E.Y. Immune reactions in different mouse strains. Bull. Exp. Biol. Med. 2002, 134:376-378.
24. Metten P., Crabbe J.C., Belknap J.K. Genetic correlates of morphine withdrawal in 14 inbred mouse strains. Drug Alcohol Depend. 2009, 99:123-131.
25. Nachum R., Shanbrom E. Rapid detection of Gram-negative bacteriuria by Limulus amoebocyte lysate assay. J. Clin. Microbiol. 1981, 13:158-162.
26. Narita M., Miyatake M., Shibasaki M., Shindo K., Nakamura A., Kuzumaki N., Nagumo Y., Suzuki T. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31:2476-2488.
27. Narita M., Suzuki M., Kuzumaki N., Miyatake M., Suzuki T. Implication of activated astrocytes in the development of drug dependence. Ann. N.Y. Acad. Sci. 2008, 1141:96-104.
28. Preacher K.J., Hayes A.F. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav. Res. Methods Instrum. Comput. 2004, 36:717-731.
29. Preacher K.J., Hayes A.F. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav. Res. Methods 2008, 40:879-891.
30. Raghavendra V., Rutkowski M.D., DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. 2002, 22:9980-9989.
31. Rock R.B., Hu S., Sheng W.S., Peterson P.K. Morphine stimulates CCL2 production by human neurons. J. Neuroinflammation 2006, 3:32.
32. Shavit Y., Wolf G., Goshen I., Livshits D., Yirmiya R. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 2005, 115:50-59.
33. Song P., Zhao Z.Q. The involvement of glial cells in the development of morphine tolerance. Neurosci. Res. 2001, 39:281-286.
34. Watkins L.R., Hutchinson M.R., Johnston I.N., Maier S.F. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 2005, 28:661-669.
35. Watkins L.R., Hutchinson M.R., Ledeboer A., Wieseler-Frank J., Milligan E.D., Maier S.F. Glia as the " bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav. Immun. 2007, 21:131-146.
36. Watkins L.R., Hutchinson M.R., Rice K.C., Maier S.F. The " toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol. Sci. 2009, 30:581-591.
37. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci. Signal. 2010, 3:cm1.
38. Wetzel M.A., Steele A.D., Eisenstein T.K., Adler M.W., Henderson E.E., Rogers T.J. Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J. Immunol. 2000, 165:6519-6524.